FDA mandates opioid label changes

The FDA announced on July 31 that it is requiring new safety labeling for all opioid painkillers to better emphasize the risks of long-term use. This decision follows a May advisory committee meeting that reviewed two observational studies showing serious dangers such as misuse, addiction and overdose. The updated labels will now include clearer guidance on dosing, duration limits, treatment plans, overdose risks and reversal, drug interactions and digestive side effects. Manufacturers have 30 days to submit their revised labels for FDA review. The move is part of broader efforts to address the ongoing opioid crisis.